News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel

News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel
Sign In

Geneticists Question Balance of Media Coverage of the Value of Gene Sequencing and Personalized Medicine

Pathologists and medical laboratory managers will want to stay informed about how genome sequencing data is being translated into clinical applications

There is a vigorous debate unfolding about the ability of personal genome sequencing to reliably predict disease. That is not news to pathologists and clinical laboratory managers. What is a novel twist in the arguments by both sides is whether media coverage has the potential to undermine public support for genomics and personalized medicine.

For example, one media story on a study of the power of personal genome sequencing to predict disease drew fire from some genomics experts on two counts. First, they questioned the validity of the study. Second, they fear that such coverage by the media could weaken public support for genomics and personalized medicine.

Public Perception of the Value of Genetic Testing

During 2012, The New York Times published a story on a study by Johns Hopkins University that sought to determine whether genetic testing can predict future disease. According to the results of this particular study, it cannot.

Some noted genomics experts took the Times—and the study—to task. One is Ronald W. Davis, Ph.D., Professor of Biochemistry and Genetics at Stanford University School of Medicine. Davis is Director of the Stanford Genome Technology Center. (more…)

Advances in Computational Medicine May Change How Physicians Use Clinical Pathology Laboratory Tests

Physicians, including pathologists, will be able to see a more holistic picture of the mechanisms of disease using sophisticated computer-generated models

Medical diagnosis and treatment will be greatly influenced by the fast-growing field of computational medicine. It is a development with the potential to significantly change how physicians use clinical laboratory tests and anatomic pathology services.

Computational medicine describes how researchers are using sophisticated software tools to map highly complex biophysical and disease pathways. This cutting-edge imaging technology enhances their ability to decipher the complex, often non-intuitive dynamics of human disease. (more…)

New Pathology Testing Device Enables Oncologists to Diagnose Cancer in One Hour at the Bedside with 96% Accuracy

Smartphone-based lab testing device could eliminate need to send biopsies to pathology laboratories

For years, pathologists have wondered when technology would make it feasible to diagnose cancer at the patient’s beside. Eliminating the need for a traditional biopsy that goes off to the anatomic pathology laboratory, and requires 24 hours or more to process the tissue and evaluate the case. Now scientists at Harvard Medical School may be close to perfecting a device that can allow oncologists to do exactly that type of bedside analysis and produce a diagnosis in 60 minutes or less!

The heart of this technology is a new microchip that interacts with smartphone software. Researchers believe it will be possible for physicians to diagnose cancer at the bedside in less than 60 minutes.

(more…)

Clinical Pathology Labs Are on Track to Get New Genetic Test That Screens for 448 Rare Childhood Diseases

Rapid gene sequencing technology will give medical laboratories a new diagnostic tool

Rapidly-evolving molecular diagnostics technology is about to trigger a major expansion in pre-conception genetic testing. In turn, this could benefit clinical laboratories and pathology groups as they begin to offer these genetic tests to help prospective parents screen their DNA for recessive gene mutations that cause 448 deadly childhood diseases in offspring.

This breakthrough medical laboratory test delivers two important benefits. First, as a universal carrier screening test, this multiplex assay greatly expands the number of diseases that can be screened at one time. Second, its next-generation sequencing (NGS) technology dramatically reduces the cost of genetic sequencing. Instead of thousands of dollars, this test only costs about $400!

(more…)

;